Akebia reports 2022 Auryxia revenue $177.1M (+24.5% YoY); net loss narrows to $92.6M

Akebia Therapeutics, Inc.

Q4 2022 net product revenue $49.7M (+18.1% YoY); full-year $177.1M, driven by pricing and payer mix.
Full-year net loss $92.6M, down from $282.8M in 2021; cash $90.5M at year-end.
Positive CHMP opinion for vadadustat (Vafseo) in Europe; potential EC approval by May 2023.
2023 Auryxia net product revenue guidance set at $175-180M, reflecting cautious market outlook.
Regained vadadustat rights globally; submitted FDA Formal Dispute Resolution Request in 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Akebia Therapeutics, Inc. reported the fiscal year ended December 31, 2022 results: revenue $292.6 million.

Period: the fiscal year ended December 31, 2022
Revenue: $292.6 million
Result: reported results

Exact text from the filing

Total revenue was $55.2 million in the fourth quarter of 2022 compared to $59.6 million for the fourth quarter of 2021, and $292.6 million for the full-year 2022 compared to $213.6 million for full-year 2021.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Akebia Therapeutics, Inc. reported the fourth quarter ended December 31, 2022 results: revenue $55.2 million.

Period: the fourth quarter ended December 31, 2022
Revenue: $55.2 million
Result: reported results

Exact text from the filing

Total revenue was $55.2 million in the fourth quarter of 2022 compared to $59.6 million for the fourth quarter of 2021

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Akebia Therapeutics, Inc. reported 2023 results: revenue $175-$180 million. Guidance initiated.

Period: 2023
Revenue: $175-$180 million
Guidance: initiated
Result: guidance update

Exact text from the filing

Sets 2023 Auryxia net product revenue guidance at $175-$180M

View on SEC.gov

Browse all earnings releases →

Akebia Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-065311

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.